LCS-1|cas:41931-13-9|西域试剂

LCS-1,99.11%

产品编号：Bellancom-115445| CAS NO：41931-13-9| 分子式：C₁₁H₈Cl₂N₂O| 分子量：255.10

LCS-1是一种超氧化物歧化酶1（SOD1）抑制剂。LCS-1抑制SOD1活性，IC50值为1.07μM。LCS-1诱导多发性骨髓瘤（MM.1S）细胞的早期和晚期凋亡。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-115445	￥500.00	杭州北京（现货）
Bellancom-115445	￥900.00	杭州北京（现货）
Bellancom-115445	￥2000.00	杭州北京（现货）
Bellancom-115445	￥3500.00	杭州北京（现货）
Bellancom-115445	￥6500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LCS-1

产品介绍

LCS-1 是一种超氧化物歧化酶 1 (SOD1) 抑制剂。LCS-1 抑制 SOD1 活性，IC₅₀ 值为 1.07 μM。LCS-1 诱导多发性骨髓瘤细胞 (MM.1S) 的早期和晚期凋亡(apoptosis)。

生物活性

LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells.

体外研究

LCS-1 (1-10000 nM; 24 hours) has selective cytotoxicity towards bloom syndrome gene product (BLM) -proficient and BLM-deficient HCT116 cells.
LCS-1 shows growth inhibitory effect on 10/27 adenocarcinoma cell lines (median IC₅₀=0.20 μM; such as H23, H2347, HCC827 cell lines) and normal human bronchial epithelial (NHBE) cells (IC₅₀=2.66 μM).
LCS-1 (0, 1.25, 2 μM; 4 h) in a concentration-dependent manner triggers significant inhibition of SOD1 enzymatic activity in multiple myeloma (MM) cells.
LCS-1 (0, 1.25, 2.5, 5 μM; 48 h) in a dose-dependent manner reduces the viability of various MM cell lines, including MM.1R (Dexamethasone-resistant), Dox40 (Doxorubicin-resistant), or LR5 (Melphalan-resistant) cell lines.
LCS-1 (48 h) has IC₅₀ values of 2.5 and 4.6 μM for cell viability of ANBL6-WT (Bortezomib-sensitive) and ANBL6-BR (Bortezomib- resistant) cells, respectively.
LCS-1 (1.25 μM; 16 h) induces a significant increase in ROS levels and O₂⁻ levels in MM.1S cells.
LCS-1 (1.25 μM; 16 h) shows a significant decrease in GSH/GSSG ratio in MM.1S cells.
LCS-1 (1.25 μM; 24h) induces the release of mitochondrial cytochrome-c into the cytosol, and enriches the proteins (HSP60/CLPP) mediating mtUPR signaling in MM.1S cells.
LCS-1-induced O₂⁻ (1.25 μM; 5 h) triggers a marked decrease in both RP₂CP and RP₁CP forms of 26S proteasomes.
LCS-1 (2 μM; 16 h) induces the early- and late-stage apoptosis of MM.1S cells.
LCS-1 (0, 0.5, 1, 1.5, 2 μM) upregulates p53/p21 signaling, as well as downregulates survival pathway proteins MCL-1, BclxL, or c-Myc in MM.1S cells.
LCS-1 (0, 4, 8, 16, 24 h; 2 μM) shows a rapid and robust induction of mitochondrial unfolded protein response (UPR) proteins (BIP, PERK, phosphorylated eIF2α, or a lectin protein calnexin) in MM.1S and ANBL6-BR cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	BLM-proficient and BLM-deficient HCT116 cells
Concentration:	1-10000 nM
Incubation Time:	24 hours
Result:	Had IC₅₀ values of 1462 nM and 24.92 nM for the viability of BLM-proficient and BLM-deficient HCT116 cells, respectively.

Western Blot Analysis

Cell Line:	MM.1S and ANBL6-BR cells
Concentration:	2 μM
Incubation Time:	16 hours
Result:	Decreased the expression of cell-cycle regulatory proteins (cyclin-B1, CDC25C, and CDC2).

Western Blot Analysis

Cell Line:	MM.1S cells
Concentration:	0, 0.5, 1, 1.5, 2 μM
Incubation Time:
Result:	Upregulated p53/p21 signaling, as well as downregulated survival pathway proteins MCL-1, BclxL, or c-Myc.

Western Blot Analysis

Cell Line:	MM.1S cells
Concentration:	2 μM
Incubation Time:	0, 4, 8, 16, 24 hours
Result:	Showed a rapid and robust induction of UPR proteins (BIP, PERK, phosphorylated eIF2α, or a lectin protein calnexin).

体内研究
(In Vivo)

LCS-1 (20 mg/kg; i.p. every other day for 14 days) inhibits MM growth and prolongs host survival in MM.1S-bearing mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-week-old female CB17 SCID mice (MM.1S tumors volume=100 mm³)
Dosage:	20 mg/kg (diluted in saline)
Administration:	Intraperitoneal injections; treated on an every other day schedule for 14 days
Result:	Inhibited MM growth and prolongs host survival.

体内研究

LCS-1 (20 mg/kg; i.p. every other day for 14 days) inhibits MM growth and prolongs host survival in MM.1S-bearing mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-week-old female CB17 SCID mice (MM.1S tumors volume=100 mm³)
Dosage:	20 mg/kg (diluted in saline)
Administration:	Intraperitoneal injections; treated on an every other day schedule for 14 days
Result:	Inhibited MM growth and prolongs host survival.

体内研究

LCS-1 (20 mg/kg; i.p. every other day for 14 days) inhibits MM growth and prolongs host survival in MM.1S-bearing mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-week-old female CB17 SCID mice (MM.1S tumors volume=100 mm³)
Dosage:	20 mg/kg (diluted in saline)
Administration:	Intraperitoneal injections; treated on an every other day schedule for 14 days
Result:	Inhibited MM growth and prolongs host survival.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (196.00 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.9200 mL	19.6002 mL	39.2003 mL
5 mM	0.7840 mL	3.9200 mL	7.8401 mL
10 mM	0.3920 mL	1.9600 mL	3.9200 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Gupta A, et al. Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules. 2018 Mar 12;19(3):803-815. [Content Brief]

. Somwar R, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A. 2011;108(39):16375-16380. [Content Brief]

. Du T, et al. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 Feb;35(2):550-561. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS06
信号词	Danger
危害声明	H301-H319
警示性声明	P301 + P310-P305 + P351 + P338
危害码 (欧洲)	T,Xi
风险声明 (欧洲)	25-36
安全声明 (欧洲)	26-45
危险品运输编码	UN 2811 6.1 / PGIII
海关编码	2933990090

1. 物质的识别

产品名：	LCS-1
CAS号：	41931-13-9
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	LCS-1
别名：	LCS1
分子式：	C11H8Cl2N2O
分子量：	255.1

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

90351-49-8

536-89-0

~10%

41931-13-9

文献：MEMORIAL SLOAN-KETTERING CANCER CENTER Patent: WO2008/80056 A2, 2008 ; Location in patent: Page/Page column 94 ;

766-40-5

536-89-0

41931-13-9

文献：Urbano, Mariangela; Guerrero, Miguel; Zhao, Jian; Velaparthi, Subash; Roberts, Edward; Adrian Saldanha, S.; Chase, Peter; Hodder, Peter; Wang, Zhiwei; Civelli, Olivier; Schaeffer, Marie-Therese; Brown, Steven; Rosen, Hugh Bioorganic and Medicinal Chemistry Letters, 2012 , vol. 22, # 23 p. 7135 - 7141,7

上游产品 2
536-89-0 766-40-5
下游产品 0

[1]. Gupta A, et al. Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells. Biomacromolecules. 2018 Mar 12;19(3):803-815.

[2]. Somwar R, et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A. 2011;108(39):16375-16380.

[3]. Du T, et al. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 Feb;35(2):550-561.

LCS-1,99.11%

LCS-1

化学品安全说明书(MSDS)

质检证书(COA)

1. 物质的识别

2. 合成/成分数据

3. 急救措施

4. 消防措施

5. 泄漏应急处理

6. 处理和储存

7. 接触控制和个人防护

8. 稳定性和反应活性

9. 毒性资料

10. 生态资料

11. 废弃处置

12. 运输信息

13. 法规信息

14. 其他信息

在线咨询